American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation

ASCO 2020 – Wrap Up

Results from the CHRYSALIS study show that amivantamab demonstrates robust and durable antitumor activity and a manageable safety profile in patients with EGFR exon20ins-mutated non–small-cell lung cancer. Read More ›

Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program

ASCO 2020 – Wrap Up

A substantial minority of patients with advanced non–small-cell lung cancer and highly actionable gene variants were not prescribed available targeted therapies in the Veterans Health Affairs National Precision Oncology Program. Read More ›

ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

ASCO 2020 – Lung Cancer

Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population. Read More ›

Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors

ASCO 2020 – Lung Cancer

The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented. Read More ›

Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade

ASCO 2020 – Lung Cancer

The characteristics of long-term responders to PD-1 blockade are presented. Read More ›

Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too

ASCO 2020 – Lung Cancer

For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit. Read More ›

Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma

ASCO 2020 – Lung Cancer

Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy. Read More ›

Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC

ASCO 2020 – Lung Cancer

Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer. Read More ›

Nationwide Genomic Screening Network Can Be Effective in Identifying Rare Targetable Genetic Alterations

ASCO 2020 – Lung Cancer

Developing novel targeted therapies for patients with cancer who have rare mutations, such as PI3K/AKT/mTOR pathway alterations, is particularly challenging for researchers. Read More ›

Cediranib Combined with Olaparib Is Active in Patients with Platinum-Pretreated SCLC

ASCO 2020 – Lung Cancer

Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor. Read More ›

American Society of Clinical Oncology (ASCO)

Page 9 of 29